Miguel Ángel González-Gay, MD, PhD

Professor Miguel A. González-Gay received his medical degree in 1980 from the University of Cantabria, Spain. He completed his residency in Rheumatology at Marqués de Valdecilla University Hospital, Santander, Spain, in 1985.

He received ECFMG Certification (USA) #390-646-8 on February 2, 1986.

From 1993 to 1995, he completed a two-year Ph.D. research fellowship at the Department of Immunology, Mayo Clinic, Rochester, MN, USA. In 1995, he obtained his Ph.D. for his research on the effect of H-2Eb gene polymorphism in protection against collagen-induced arthritis and its role in HLA-DRB1 molecules in rheumatoid arthritis. He was awarded the Extraordinary Doctorate Award from the University of Cantabria. In 2018, he was accredited as a Full Professor by ANECA, Spain's National Agency for Quality Assessment and Accreditation.

He served as Rheumatology staff at Xeral-Calde Lugo Hospital, Spain, from 1987 to 2009. He then became Head of the Rheumatology Section at Marqués de Valdecilla University Hospital (Santander) from 2010 to 2015, followed by his role as Head of the Rheumatology Division at the University Clinical Hospital of Santiago de Compostela, Spain (October 2015–February 2016). From 2017 to December 2022, he was Head of the Rheumatology Division at Marqués de Valdecilla University Hospital and Director of the Research Group on Epidemiology, Genetics, and Atherosclerosis of Systemic Inflammatory Diseases at IDIVAL (Santander, Spain).

Currently, he is a Full Professor of Medicine at the Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain, and a Clinical Researcher at the Rheumatology Division of Fundación Jiménez Díaz University Hospital, Madrid, Spain.

His research focuses on the epidemiology and genetics of autoimmune diseases, particularly systemic vasculitis, including giant cell arteritis and IgA vasculitis (Henoch-Schönlein purpura). Since 2000, Dr. González-Gay has also led research on atherosclerosis, cardiovascular disease and metabolic syndrome in rheumatic diseases, such as rheumatoid arthritis and systemic lupus erythematosus.

He received five consecutive 3-year grants from the “Carlos III Health Institute – Health Research Fund” (Spain) to study genetic markers of endothelial dysfunction, subclinical atherosclerosis, and cardiovascular disease in patients with rheumatoid arthritis and other chronic inflammatory rheumatic diseases.He is currently the recipient of a grant from the 'Carlos III Health Institute – Health Research Fund' (Spain) for research on non-alcoholic fatty liver disease in rheumatoid arthritis.

In addition to his clinical and research work, Prof. González-Gay prioritizes teaching medical students and residents.

He has over 1,100 publications in PubMed, primarily listed as “Gonzalez-Gay MA” (alternatively “Gonzalez-Gay M” or "Gonzalez-Gay Mantecon MA”). He has supervised 29 thesis projects.

H-indexes (as of October 13 , 2026):

Search in:

1)Web of Science Core Collection Science Citation Index Expanded

(SCI-EXPANDED)--1900-present: 105

(Search as: AU=(GONZALEZ*GAY MOR MANTECON MAG OR GAYMAG) AND AD=(VALDECILLA ORLUGO OR MAYOOR LANCS ORR*EUMATOL OR JIMENEZ DIAZ OR CANTABRIA)NOT UT=(000485817300003 OR000485817300009) NOT TI=(PGOR VOL)

2) Scopus: 108

3) Google Scholar: 125

On December 31, 2021, his cumulative impact factor was 4,422.224 (PubMed).